Novocure announced on Tuesday that the FDA approved its Optune Lua wearable device for treating metastatic non-small cell lung cancer.
Optune Lua uses tumor-treating fields (TTFields) to exert physical forces on the electrically charged components of dividing cancer cells. This results in cell death.
The FDA approved the device for concurrent use with PD-1/PD-L1 inhibitors or docetaxel to treat mNSCLC patients who have progressed on or after a platinum-based regimen.
“Novocure is committed to extending survival in some of the most aggressive and difficult to treat cancers. The approval of Optune Lua brings a new and urgently needed option for people with metastatic NSCLC who have progressed while on or after platinum-based chemotherapy,” said Asaf Danziger, CEO, Novocure. “We are grateful to the patients, caregivers, investigators and healthcare providers who supported the clinical trials that led to this approval.”
